Pfizer Wins FDA Approval for Use of Prevnar 13 in Vaccine-Naive Children, Adolescents Aged 6-17 for Prevention of Invasive Pneumococcal Disease
Posted on January 25, 2013 at 16:23 PM EST
Pfizer Inc. (NYSE: PFE ) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13^®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM[197] Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for